142 related articles for article (PubMed ID: 29658435)
1. Combined Immunotherapy (OK-432, IL-2) With Chemotherapy Decrease the Recurrence Rate in Advanced Ovarian Cancer.
Wang YL; Peng HH; Su SY; Lin CT
Reprod Sci; 2019 Feb; 26(2):244-249. PubMed ID: 29658435
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory therapy in refractory/recurrent ovarian cancer.
Chen CY; Lai CH; Yang LY; Tang YH; Chou HH; Chang CJ; Lin CT
Taiwan J Obstet Gynecol; 2015 Apr; 54(2):143-9. PubMed ID: 25951718
[TBL] [Abstract][Full Text] [Related]
3. [Value of CA(125) in the prediction of optimal interval debulking surgery and its prognosis in patients with epithelial ovarian cancer].
Mu T; Li XP; Wang JL; Wang SJ; Wang Y; Sun XL; Cui H; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Aug; 47(8):566-70. PubMed ID: 23141174
[TBL] [Abstract][Full Text] [Related]
4. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
[TBL] [Abstract][Full Text] [Related]
5. Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study.
Gadducci A; Cosio S; Zizioli V; Notaro S; Tana R; Panattoni A; Sartori E
Int J Gynecol Cancer; 2017 Jan; 27(1):28-36. PubMed ID: 27870700
[TBL] [Abstract][Full Text] [Related]
6. Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center.
Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
J Gynecol Oncol; 2018 Jul; 29(4):e63. PubMed ID: 29770632
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery.
Ghaemmaghami F; Karimi-Zarchi M; Modares-Gilani M; Mousavi A; Behtash N
Asian Pac J Cancer Prev; 2008; 9(4):719-24. PubMed ID: 19256766
[TBL] [Abstract][Full Text] [Related]
8. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
9. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
[TBL] [Abstract][Full Text] [Related]
10. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens.
Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE
Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799
[TBL] [Abstract][Full Text] [Related]
11. Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women.
Chishti U; Aziz AB
J Pak Med Assoc; 2015 Mar; 65(3):306-9. PubMed ID: 25933567
[TBL] [Abstract][Full Text] [Related]
12. Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy.
Petrillo M; Ferrandina G; Fagotti A; Vizzielli G; Margariti PA; Pedone AL; Nero C; Fanfani F; Scambia G
Ann Surg Oncol; 2013 Nov; 20(12):3955-60. PubMed ID: 23838915
[TBL] [Abstract][Full Text] [Related]
13. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
14. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
[TBL] [Abstract][Full Text] [Related]
15. [Comparative study of different chemotherapy approaches for advanced epithelial ovarian cancer].
Chen YL; Liu YQ; Tang DH; Chu CN
Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):110-4. PubMed ID: 18683749
[TBL] [Abstract][Full Text] [Related]
16. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
[TBL] [Abstract][Full Text] [Related]
17. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
[TBL] [Abstract][Full Text] [Related]
18. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
Bian C; Yao K; Li L; Yi T; Zhao X
Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
[TBL] [Abstract][Full Text] [Related]
19. Optimal debulking surgery followed by paclitaxel/platinum chemotherapy is very effective in treating ovarian carcinosarcomas: a single center experience.
Chun KC; Kim JJ; Kim DY; Kim JH; Kim YM; Nam JH; Kim YT
Gynecol Obstet Invest; 2011; 72(3):208-14. PubMed ID: 21968161
[TBL] [Abstract][Full Text] [Related]
20. Advanced ovarian cancer treated by intraperitoneal immunotherapy with OK-432.
Kawagoe K; Masuda H
Jpn J Clin Oncol; 1986 Jun; 16(2):137-42. PubMed ID: 3735703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
